- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05292508
Comparison of Rates of Antimicrobial Use in Febrile Patients With or Without the Use of C-reactive Protein Blood Test (CREATIB)
Rapid Diagnostic Testing for C-reactive Protein to Differentiate Bacterial and Viral Infection in Febrile Patients to Reduce Antimicrobial Use in Remote Health Care Centers of Gulmi District of Nepal: a Cluster Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
The World Health Organization (WHO) defines antimicrobial resistance (AMR) as a situation where drugs used to treat microbial infection caused by bacteria, viruses, fungi and parasites no longer work to treat infection because of the changes in these microbes over time. Though this process of development of AMR is a natural process, it is accelerated by the overuse and misuse of antimicrobials (Mladenovic-Antic et al, 2016, pp.532-537). There were an estimated 1.27 million deaths attributable to bacterial AMR globally in 2019 (Murray et al, 2022). It is estimated that in India every year around sixty thousand newborns die due to AMR (Laxminarayan et al, 2013, pp.1057-1098). As big as the death toll due to AMR is, the economic costs are also significant. Even in a setting of a developed country like the US, direct healthcare cost of AMR is over 6 billion US dollars (CDC, 2019). Nepal is one of the developing countries of the world located in South Asia between India and China. AMR is an increasing problem in Nepal and some of the most common causes for it are excessive use of antimicrobials in animal husbandry and unnecessary use of antimicrobials for treatment of febrile illness (Rijal et al, 2021, pp. 1-14; Acharya and Wilson, 2021, p.105). Currently, bacteria like Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Shigella spp., Vibrio cholera, Neisseria gonorrheae and Staphylococcus aureus are increasingly resistant to the most first-line and some second-line antimicrobials (Acharya and Wilson, 2021 p.105; Basnyat et al, 2015, pp.102-111). Thus antimicrobial resistance (AMR) presents a great threat to public health.
Nepal has its own National Antibiotic Treatment Guideline and according to this even the smallest government healthcare units like health posts can prescribe antimicrobials. These health posts lack microbiology laboratory access and the health worker has to prescribe antimicrobials based upon their history and examination findings which may lead to unnecessary prescription of antimicrobials against viral illness. This challenge of unavailability of laboratory tests can be tackled by introducing point-of-care rapid diagnostic test to detect C-reactive protein to differentiate between bacterial and viral infections. C-reactive protein is the marker of inflammation which rises in blood during bacterial infection but rarely rises during viral infection (Phommasone et al, 2015, pp.1-6). This method has already been used in other developing countries like Laos, Thailand, Myanmar, Malaysia and Vietnam, which have similar socio-economic conditions like that of Nepal (Phommasone et al, 2015, pp.1-6; Althaus et al, 2019, pp.e119-e131; Lubell et al, 2018, pp.1-6; Haenssgen et al, 2018, pp.1-12). Antimicrobials are rarely prescribed based on an absolute certainty of a bacterial infection. The use of point-of-care rapid diagnostic test offers an easy, affordable and a working solution to this problem and helps in judicial use of antimicrobials (O'Neill, 2016). Although it is known that CRP testing can differentiate bacterial and viral infections, the extent to which it can reduce antimicrobial use in a rural health-post setting of Nepal and thus play a role in limiting the emergence of antimicrobial resistance is not known. If this study shows significant reduction in antimicrobial prescription without any adverse clinical outcome, the test kit can be implemented nationally in all low resource health care settings in Nepal.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Uttam Pachya, MBBS, MD
- Phone Number: +9779851188826
- Email: uttampachya@gmail.com
Study Contact Backup
- Name: Amit Arjyal, MBBS, DPhil
- Phone Number: +9779864478329
- Email: amitarjyal@pahs.edu.np
Study Locations
-
-
Lumbini
-
Resunga Nagarpalika, Lumbini, Nepal
- Recruiting
- Paralmi Health Post
-
Contact:
- Amit Arjyal, MBBS, DPhil
- Phone Number: +9779864478329
- Email: amitarjyal@pahs.edu.np
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- History of reported fever or fever greater than 100.4◦F (38◦C) with duration of illness up to 7 days
- Duration of fever less than or equal to 7 days
- Can connect with mobile phone for follow up
Exclusion Criteria:
- Child younger than 1 year
- Main complaint being trauma or injury
- Symptoms requiring hospital referral
- Impaired consciousness
- Inability to take oral medication
- Convulsions
- Confirmed malaria
- Confirmed urinary tract infection
- Local skin infection
- Dental abscess or infection
- Suspicion of tuberculosis
- Any symptom other than fever present for more than 14 days
- Any bleeding such as from skin, nose and gums.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CRP Tests in addition to Usual Standard of Care
For the clusters (health posts) in this arm, the health worker will prick the finger of the eligible patient using a lancet device following aseptic precautions.
A very small drop (10 microliters) of whole blood will be obtained which will be added to specimen dilution buffer and the dipstick will be placed into the diluted sample.
It will be removed after the liquid rises and the timer will be started and result will be interpreted in 5 minutes.
Interpretation of CRP levels: Only red color line (No blue line): <10 mg/L One blue line: 10-40 mg/L Two blue lines: 40-80 mg/L Three blue lines: >80 mg/L.
CRP levels of 40 mg/L or above will be considered as increased CRP levels.
The decision on antimicrobial use and other treatments will be made with the help of CRP results in addition to information obtained from the history and physical examination.
|
In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed.
In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions.
A very small drop (10 microliters) of whole blood will be obtained.
This will be added to specimen dilution buffer.
Then the sample will be mixed by inverting the tube upside down 10-15 times.
Then the yellow dip area of the dipstick will be placed into the diluted sample.
It will be held there until the liquid rises to the result area by capillary action.
The the dipstick is removed from the solution and placed in a horizontal position.
The timer will be started and result will be interpreted in 5 minutes.
Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
|
No Intervention: Usual Standard of Care Alone
For the clusters (health posts) in this control arm, Usual Standard of Care Alone will be provided.
This usual standard of care is given to patients with febrile illness at health posts.
Commonly, this involves taking a brief history and conducting a simple physical examination followed by symptomatic treatment such as paracetamol, cough medication or analgesics such as NSAIDs.
Often antimicrobial treatment is also prescribed based on clinical suspicion of bacterial infection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use of antimicrobial
Time Frame: On the 1 day of recruitment to the study
|
The investigators will record if the patient was prescribed antimicrobial at the time of presenting to the health post during the current acute febrile illness.
This outcome will be recorded as Yes/No
|
On the 1 day of recruitment to the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complicated Illness
Time Frame: One month from recuitment
|
The investigators will record this as outcome of disease after contacting the patient at one month of recruitment and ask whether the patient developed any complications or not.
This outcome will be recorded as Complicated Illness (Yes/No).
Complicated illness will be defined as need for prolonged course of treatment for more than one week, need to change the initial treatment provided at the health post and give rescue treatment, any severe illness or death.
This outcome will be recorded as Yes/No
|
One month from recuitment
|
Referral to hospital
Time Frame: One month from recruitment
|
The investigators will record this outcome after contacting the patient at one month of recruitment and ask whether the patient was referred to a hospital.
This outcome will be recorded as Yes/No
|
One month from recruitment
|
Admission to hospital
Time Frame: One month from recuitment
|
The investigators will record this outcome after contacting the patient at one month of recruitment and ask whether the patient was admitted to hospital.
This outcome will be recorded as Yes/No
|
One month from recuitment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Amit Arjyal, MBBS, DPhil, Patan Academy of Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Febrile Illness
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Shoklo Malaria Research Unit... and other collaboratorsRecruitingAcute Febrile IllnessBangladesh, Lao People's Democratic Republic, Thailand
-
Swiss Tropical & Public Health InstituteSwiss National Science FoundationCompletedAcute Febrile IllnessTanzania
-
Foundation for Innovative New Diagnostics, SwitzerlandCompleted
-
Ina-RespondNational Institute of Allergy and Infectious Diseases (NIAID); National Institute...CompletedAcute Febrile IllnessIndonesia
-
Institute of Tropical Medicine, BelgiumUniversity of GondarCompleted
-
Foundation for Innovative New Diagnostics, SwitzerlandIndian Council of Medical Research; University of Oxford; WHO, Special Programme...CompletedAcute Febrile IllnessUganda, Burkina Faso, Ghana, India, Nepal
-
Hillel Yaffe Medical CenterUnknown
-
University of AarhusCompletedMetabolic Diseases | Inflammation | Febrile Illness AcuteDenmark
-
Foundation for Innovative New Diagnostics, SwitzerlandMinistry of Health, Senegal; Institut Pasteur de DakarRecruitingPneumonia | Diarrhea | Malaria | Dengue | Acute Febrile Illness | Influenza -Like IllnessSenegal
-
Seattle Children's HospitalCompletedCritical Illness | Febrile IllnessKenya
Clinical Trials on C-reactive Protein Rapid Diagnostic Test
-
Hôpital Européen MarseilleRecruiting
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedFever | MalariaAfghanistan
-
Henning BliddalCompleted
-
Central Hospital, Nancy, FranceCompletedCrohn DiseaseFrance
-
Corporacion Parc TauliUnknown
-
Moroccan Society of SurgeryRecruitingAnastomotic Leak | Digestive System Neoplasm | C-Reactive ProteinMorocco
-
Sisli Hamidiye Etfal Training and Research HospitalCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedPneumonia | Fever | Malaria | Acute Febrile IllnessAfghanistan
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversity of Khartoum; Eijkman Institute for Molecular BiologyCompletedMalaria | Diagnoses Disease | RDTSudan, Indonesia
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversity of Khartoum; Universidad Peruana Cayetano Heredia; Eijkman Institute...CompletedMalaria | Diagnoses Disease | RDTIndonesia, Peru, Sudan